Delta Asia International Corporation (6762) AI Stock Analysis

Delta Asia International Corporation

(TPEx:6762)

Select Model

Rating:40Underperform

Price Target:TWD 133.00▼(-9.52% Downside)

Action:initiatedcoverage

Date:11/10/26

Weak financial performance from margin compression and high leverage is the primary drag, followed by overvaluation and bearish technical momentum.

Positive Factors

Renewed Positive Cash FlowPositive operating cash flow in 2025 and a return to positive free cash flow provide an internal funding base for operations and investment. Although conversion remains uneven, renewed positive FCF improves financial resilience versus the prior negative-FCF period and supports liquidity over coming quarters.

Negative Factors

Inconsistent Revenue TrendThe reversal from strong revenue growth in 2023–2024 to negative growth in 2025 weakens confidence in the demand trajectory. Uneven top-line performance makes planning and resource allocation less predictable and limits visibility into sustained earnings growth over coming quarters.

Delta Asia International Corporation (6762) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 5.41B
Dividend Yield: 0.34%
Average Volume (3M): 4,439
Price to Earnings (P/E): 327.9
Beta (1Y): 0.18
Revenue Growth: -3.30%
EPS Growth: -69.37%
Country: TW
Employees: 220
Sector: General
Sector Strength: 55
Industry: Medical - Devices

Delta Asia International Corporation Business Overview & Revenue Model

Company Description

Delta Asia International Corporation, headquartered in Taoyuan City, Taiwan, specializes in the production and distribution of both components and finished goods for the medical device industry. This Taiwanese firm commenced operations in 2004.

Delta Asia International Corporation Financial Statement Overview

Summary

Revenue recovery is undermined by sharp gross margin compression to ~27% and net margins of 3.4%, alongside rising leverage with debt-to-equity above 1.0 and ROE below 2%.

Income Statement

42Neutral

Balance Sheet

28Negative

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	678.17M	694.15M	580.51M	508.02M	462.97M	531.32M
Gross Profit	161.47M	192.56M	140.10M	208.72M	233.94M	257.20M
EBITDA	264.30M	265.49M	246.99M	187.37M	278.49M	226.06M
Net Income	17.57M	23.43M	57.19M	85.78M	171.30M	130.25M
Balance Sheet
Total Assets	2.75B	2.81B	3.19B	3.02B	1.83B	1.58B
Cash, Cash Equivalents and Short-Term Investments	177.64M	171.41M	440.38M	368.23M	337.27M	787.09M
Total Debt	1.32B	1.38B	1.73B	1.65B	509.87M	432.13M
Total Liabilities	1.45B	1.50B	1.90B	1.79B	652.05M	516.34M
Stockholders Equity	1.30B	1.31B	1.29B	1.24B	1.18B	1.07B
Cash Flow
Free Cash Flow	107.04M	79.51M	-6.71M	-1.08B	-466.43M	60.62M
Operating Cash Flow	180.48M	218.09M	186.28M	87.69M	255.63M	72.82M
Investing Cash Flow	-94.21M	-26.18M	-329.19M	-1.17B	-722.06M	-12.17M
Financing Cash Flow	-133.19M	-327.10M	81.29M	1.11B	16.62M	-175.82M

Delta Asia International Corporation Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6762 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4166	70Outperform	TWD 5.47B	22.88	―	―	―	―
TW:4126	68Neutral	TWD 5.39B	12.59	―	6.06%	1.32%	7.25%
TW:4746	64Neutral	TWD 5.43B	11.40	―	6.64%	-2.71%	―
TW:1788	63Neutral	TWD 5.57B	14.20	―	5.60%	7.58%	13.04%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4164	55Neutral	TWD 4.79B	21.54	―	4.52%	11.83%	27.86%
TW:6762	40Underperform	TWD 5.43B	327.90	―	0.34%	-3.30%	-69.37%

* General Sector Average

Performance Comparison

TW:6762 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6762	Delta Asia International Corporation	147.00	-39.14	-21.03%
TW:1788	Hi-Clearance Inc.	125.00	-5.42	-4.16%
TW:4126	Pacific Hospital Supply Co., Ltd.	74.30	-9.30	-11.13%
TW:4164	CHC Healthcare Group	24.50	-16.07	-39.61%
TW:4166	Orient Pharma Co., Ltd.	22.50	-2.10	-8.54%
TW:4746	Formosa Laboratories, Inc.	45.15	-16.14	-26.33%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Delta Asia International Corporation AI Stock Analysis